Vandetanib has been approved for patients with unresectable and/or metastatic medullary thyroid cancer (MTC) by the Food and Drug Administration, by the European Medicines Agency and, very recently, it has been licensed also by the Italian Regulatory Agency (AIFA) for the use in Italy. Vandetanib is an orally tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET signaling. Circulating microRNAs levels could be influenced by the treatment procedures and we hypothesize that a TKI therapy could influence the levels of circulating miRNAs as well. Aim of this project is to seek non-invasive molecular markers potentially useful as prognostic tools for metastatic MTC patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Validation of a miRNA profile
Timeframe: 8 months
Define any correlations between the miRNA profiles and RET, and H- and K-RAS mutations
Timeframe: 8 months
Define a circulating miRNA profile
Timeframe: 8 months
Analyze any change in circulating miRNAs
Timeframe: 8 months
Correlate circulating miRNA profile with the burden of disease
Timeframe: 8 months
Evaluate the correlation between the response to vandetanib and the patients molecular profile
Timeframe: 8 months